10-KPeriod: FY1995

BRISTOL MYERS SQUIBB CO Annual Report, Year Ended Dec 31, 1995

Filed March 28, 1996For Securities:BMYCELG-RIBMYMP

Summary

This 10-K filing from Bristol Myers Squibb Co. for the period ending December 30, 1995, and filed in March 1996, provides a snapshot of the company's financial health and operational status at that time. As a significant player in the pharmaceutical industry, investors would be interested in its product portfolio, research and development pipeline, and overall financial performance. The filing would detail revenues, expenses, assets, liabilities, and critical disclosures regarding the company's business operations and risk factors. Given the era, key areas of focus for investors would likely include the company's performance in its established drug markets, potential breakthroughs from its R&D efforts, and any strategic initiatives or acquisitions that could shape its future growth. The competitive landscape, regulatory environment, and any patent expirations or challenges would also be crucial considerations for assessing the company's long-term value and investment potential.

Key Highlights

  • 1Bristol Myers Squibb Co. filed its 10-K annual report for the fiscal year ending December 30, 1995, on March 27, 1996.
  • 2The filing provides a comprehensive overview of the company's financial position, including revenues, expenses, assets, and liabilities for the 1995 fiscal year.
  • 3Investors can gain insights into the company's product lines and their performance within the pharmaceutical market during 1995.
  • 4Information regarding the company's research and development activities and pipeline is a critical component for assessing future growth potential.
  • 5The report likely contains detailed discussions of business strategies, market risks, and competitive landscape for Bristol Myers Squibb.
  • 6Key financial statements and management's discussion and analysis (MD&A) are central to understanding the company's operational performance and outlook.

Frequently Asked Questions

The 10-K filing details the financial performance for the fiscal year ending December 30, 1995. Investors should review the consolidated statements of operations and the Management's Discussion and Analysis (MD&A) section for a comprehensive understanding of revenues, profitability, and key financial metrics.

The filing typically breaks down revenue by product lines or major therapeutic areas. Investors should look for disclosures within the 'Business' or 'Management's Discussion and Analysis' sections to identify the primary revenue drivers and assess their market performance.

The 'Research and Development' section of the 10-K filing would outline the company's R&D spending, key ongoing projects, and any significant advancements or clinical trial results reported during the year. This is crucial for evaluating the company's future growth prospects.

The 'Risk Factors' or 'Management's Discussion and Analysis' sections would describe potential challenges, including regulatory hurdles, patent expirations, competitive pressures, and economic conditions, that could impact the company's future financial performance.